Aditxt

Aditxt Equity Ratio

The Equity Ratio of Aditxt (ADTX) as of Nov 3, 2026 is 33.96 %. In the previous year, Equity Ratio was 25.78 % — a change of 31.75% (higher).

Equity Ratio

33.96 %

YoY

31.75%

Last updated:

Equity Ratio of Aditxt is 2025 33.96 % . Equity Ratio of Aditxt was 2024 25.78 % . It decreases by 31.75% higher compared to the previous year.

The Aditxt Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
-1,328.10 USD
Jan 1, 2019
-2,308.86 USD
Jan 1, 2020
84.08 USD
Jan 1, 2021
61.09 USD
Jan 1, 2022
48.50 USD
Jan 1, 2023
36.00 USD
Jan 1, 2024
25.78 USD
Jan 1, 2025
33.96 USD
The Aditxt Equity Ratio history
YEAREquity RatioYoY
33.96 %+31.75%
25.78 %-28.39%
36.00 %-25.78%
48.50 %-20.62%
61.09 %-27.34%
84.08 %-103.64%
-2,308.86 %+73.85%
-1,328.10 %+454.30%
-239.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aditxt Stock analysis

What does Aditxt do? ADiTx Therapeutics, Inc. develops nucleic acid-based technologies for organ transplant tolerance and immune system health. The company's Apoptotic DNA Immunotherapy (ADi) reprograms the immune system to induce tolerance, while Aditxt Immune Monitor (AiM) provides personalized immune profiles. Both technologies are in preclinical development, with the firm focusing on minimizing transplant rejection and addressing autoimmune diseases and allergies. The company is headquartered in Mountain View, California and employs 2 full-time staff. ADiTx Therapeutics, Inc. generates revenue through the development and potential future commercialization of its immune reprogramming and monitoring technologies. The company is a preclinical stage life sciences entity targeting medical applications in organ transplantation and immune-related conditions. Its core products, ADi and AiM, are designed to address unmet medical needs in immune system management. The firm's focus on immune reprogramming and monitoring positions it for potential partnerships with healthcare providers and biopharmaceutical companies in the future. Aditxt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aditxt stock

Equity Ratio of Aditxt is 33.96 % in 2025.

Equity Ratio of Aditxt changed from 25.78 % to 33.96 %, representing a 31.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Aditxt since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Aditxt with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Aditxt

All Key Metrics — Aditxt